Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
10
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer's disease: A prospective study in eight cohorts

      1 , 2 , 3 , 4 , 5 , 1 , 3 , 6 , 3 , 6 , 2 , 3 , 6 , 3 , 6 , 7 , 8 ,   8 , 9 , 10 , 11 , 12 , 13 , 7 , 14 , 15 , 16 , 5 , 5 , 17 , 18 , 5 , 19 , 20 , 21 , 22 , 7 , 15 , 16 , 16 , 14 , 14 , 23 , 24 , 23 , 24 , 25 , 26 , 27 , 3 , 28 , 8 , 29 , 5 , 30 , 2 , 3 , 31 , 7
      Alzheimer's & Dementia
      Elsevier BV

      Read this article at

      ScienceOpenPublisher
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction Metabolite, lipid, and lipoprotein lipid profiling can provide novel insights into mechanisms underlying incident dementia and Alzheimer’s disease. Methods We studied eight prospective cohorts with 22,623 participants profiled by nuclear magnetic resonance or mass spectrometry metabolomics. Four cohorts were used for discovery with replication undertaken in the other four to avoid false positives. For metabolites that survived replication, combined association results are presented. Results Over 246,698 person-years, 995 and 745 cases of incident dementia and Alzheimer’s disease were detected, respectively. Three branched-chain amino acids (isoleucine, leucine, and valine), creatinine and two very low density lipoprotein (VLDL)-specific lipoprotein lipid subclasses were associated with lower dementia risk. One high density lipoprotein (HDL; the concentration of cholesterol esters relative to total lipids in large HDL) and one VLDL (total cholesterol to total lipids ratio in very large VLDL) lipoprotein lipid subclass was associated with increased dementia risk. Branched-chain amino acids were also associated with decreased Alzheimer’s disease risk and the concentration of cholesterol esters relative to total lipids in large HDL with increased Alzheimer’s disease risk. Discussion Further studies can clarify whether these molecules play a causal role in dementia pathogenesis or are merely markers of early pathology.

          Related collections

          Most cited references22

          • Record: found
          • Abstract: found
          • Article: not found

          Metabolic network failures in Alzheimer's disease: A biochemical road map.

          The Alzheimer's Disease Research Summits of 2012 and 2015 incorporated experts from academia, industry, and nonprofit organizations to develop new research directions to transform our understanding of Alzheimer's disease (AD) and propel the development of critically needed therapies. In response to their recommendations, big data at multiple levels are being generated and integrated to study network failures in disease. We used metabolomics as a global biochemical approach to identify peripheral metabolic changes in AD patients and correlate them to cerebrospinal fluid pathology markers, imaging features, and cognitive performance.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            2-Aminoadipic acid is a biomarker for diabetes risk.

            Improvements in metabolite-profiling techniques are providing increased breadth of coverage of the human metabolome and may highlight biomarkers and pathways in common diseases such as diabetes. Using a metabolomics platform that analyzes intermediary organic acids, purines, pyrimidines, and other compounds, we performed a nested case-control study of 188 individuals who developed diabetes and 188 propensity-matched controls from 2,422 normoglycemic participants followed for 12 years in the Framingham Heart Study. The metabolite 2-aminoadipic acid (2-AAA) was most strongly associated with the risk of developing diabetes. Individuals with 2-AAA concentrations in the top quartile had greater than a 4-fold risk of developing diabetes. Levels of 2-AAA were not well correlated with other metabolite biomarkers of diabetes, such as branched chain amino acids and aromatic amino acids, suggesting they report on a distinct pathophysiological pathway. In experimental studies, administration of 2-AAA lowered fasting plasma glucose levels in mice fed both standard chow and high-fat diets. Further, 2-AAA treatment enhanced insulin secretion from a pancreatic β cell line as well as murine and human islets. These data highlight a metabolite not previously associated with diabetes risk that is increased up to 12 years before the onset of overt disease. Our findings suggest that 2-AAA is a marker of diabetes risk and a potential modulator of glucose homeostasis in humans.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Is dementia incidence declining?: Trends in dementia incidence since 1990 in the Rotterdam Study.

              To investigate whether dementia incidence has changed over the last 2 decades. We compared dementia incidence in 2 independent subcohorts of persons aged 60-90 years from the Rotterdam Study, a population-based cohort study. The first subcohort started in 1990 (n = 5,727), the second in 2000 (n = 1,769). Participants were dementia-free at baseline and followed for at maximum 5 years. We calculated age-adjusted dementia incidence rates for the 2 subcohorts in total, in 10-year age strata, and for men and women separately. We also compared mortality rates, differences in prevalence of vascular risk factors, and medication use. Finally, we compared brain volumes and the extent of cerebral small vessel disease in participants who underwent brain imaging 5 years after the baseline examinations. In the 1990 subcohort (25,696 person-years), 286 persons developed dementia, and in the 2000 subcohort (8,384 person-years), 49 persons. Age-adjusted dementia incidence rates were consistently, yet nonsignificantly, lower in the 2000 subcohort in all strata, reaching borderline significance in the overall analysis (incidence rate ratio 0.75, 95% confidence interval [CI] 0.56-1.02). Mortality rates were also lower in the 2000 subcohort (rate ratio 0.63, 95% CI 0.52-0.77). The prevalence of hypertension and obesity significantly increased between 1990 and 2000. This was paralleled by a strong increase in use of antithrombotics and lipid-lowering drugs. Participants in 2005-2006 had larger total brain volumes (p < 0.001) and less cerebral small vessel disease (although nonsignificant in men) than participants in 1995-1996. Although the differences in dementia incidence were nonsignificant, our study suggests that dementia incidence has decreased between 1990 and 2005.
                Bookmark

                Author and article information

                Journal
                ALZ
                Alzheimer's & Dementia
                Alzheimer's & Dementia
                Elsevier BV
                15525260
                June 2018
                June 2018
                March 05 2018
                : 14
                : 6
                : 723-733
                Affiliations
                [1 ]Department of Cardiology; Tays Heart Hospital; Tampere University Hospital and Faculty of Medicine and Life Sciences; University of Tampere; Tampere Finland
                [2 ]Department of Neurology; Boston University School of Medicine; Boston MA USA
                [3 ]The Framingham Heart Study; Framingham MA USA
                [4 ]Lille University; Inserm; Lille University Hospital; Institut Pasteur de Lille; U1167 - RID-AGE - Risk Factors and Molecular Determinants of Aging-Related Diseases; Labex Distalz; Lille France
                [5 ]Department of Epidemiology; ErasmusMC; Rotterdam The Netherlands
                [6 ]Department of Biostatistics; Boston University School of Public Health; Boston MA USA
                [7 ]Department of Health; National Institute for Health and Welfare; Helsinki Finland
                [8 ]Department of Epidemiology and Public Health; University College London; London UK
                [9 ]INSERM, U1018; Centre for Research in Epidemiology and Population Health; France
                [10 ]Cardiology Division, Department of Medicine; Massachusetts General Hospital; Harvard Medical School; Boston MA USA
                [11 ]Broad Institute of MIT and Harvard; Cambridge MA USA
                [12 ]Cardiovascular Research Center; Massachusetts General Hospital; Harvard Medical School; Boston MA USA
                [13 ]Vanderbilt Heart and Vascular Institute; Vanderbilt University School of Medicine; Nashville TN USA
                [14 ]Nightingale Health Ltd; Helsinki Finland
                [15 ]Research Programs Unit; Diabetes and Obesity; University of Helsinki; Helsinki Finland
                [16 ]Estonian Genome Center; University of Tartu; Tartu Estonia
                [17 ]Department of Radiology and Nuclear Medicine; Erasmus MC; Rotterdam The Netherlands
                [18 ]Department of Neurology; Erasmus MC; Rotterdam The Netherlands
                [19 ]Department of Clinical Chemistry; Fimlab Laboratories; Tampere Finland
                [20 ]Department of Clinical Chemistry; Finnish Cardiovascular Research Center - Tampere; Faculty of Medicine and Life Sciences; University of Tampere; Tampere Finland
                [21 ]Department of Clinical Physiology; Tampere University Hospital; Tampere Finland
                [22 ]Department of Clinical Physiology; Finnish Cardiovascular Research Center - Tampere; Faculty of Medicine and Life Sciences; University of Tampere; Tampere Finland
                [23 ]Computational Medicine; Faculty of Medicine; University of Oulu and Biocenter Oulu; Oulu Finland
                [24 ]NMR Metabolomics Laboratory; School of Pharmacy; University of Eastern Finland; Kuopio Finland
                [25 ]Population Health Science; Bristol Medical School; University of Bristol; Bristol UK
                [26 ]Medical Research Council Integrative Epidemiology Unit at the University of Bristol; Bristol UK
                [27 ]Systems Epidemiology; Baker Heart and Diabetes Institute; Melbourne Victoria Australia. Department of Epidemiology and Preventive Medicine; School of Public Health and Preventive Medicine; Faculty of Medicine; Nursing and Health Sciences; The Alfred Hospital; Monash University; Melbourne Victoria Australia
                [28 ]Department of Medicine, Sections of Preventive Medicine and Cardiology; Boston University School of Medicine; Boston MA USA
                [29 ]Clinicum; Faculty of Medicine; University of Helsinki; Helsinki Finland
                [30 ]Leiden Academic Center for Drug Reseach (LACDR); Leiden University; Leiden The Netherlands
                [31 ]Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases; University of Texas Health Sciences Center; San Antonio TX USA
                Article
                10.1016/j.jalz.2018.01.003
                02f9cd19-1313-43b7-ae24-432000218e87
                © 2018

                http://doi.wiley.com/10.1002/tdm_license_1.1

                https://www.elsevier.com/tdm/userlicense/1.0/

                http://creativecommons.org/licenses/by-nc-nd/4.0/

                History

                Comments

                Comment on this article